Aura Biosciences (AURA) Competitors $6.59 +0.13 (+2.01%) As of 07/3/2025 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AURA vs. GPCR, CVAC, CALT, AUPH, BGM, NAGE, AMPH, DYN, ABCL, and PAHCShould you be buying Aura Biosciences stock or one of its competitors? The main competitors of Aura Biosciences include Structure Therapeutics (GPCR), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Aurinia Pharmaceuticals (AUPH), BGM Group (BGM), Niagen Bioscience (NAGE), Amphastar Pharmaceuticals (AMPH), Dyne Therapeutics (DYN), AbCellera Biologics (ABCL), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical products" industry. Aura Biosciences vs. Its Competitors Structure Therapeutics CureVac Calliditas Therapeutics AB (publ) Aurinia Pharmaceuticals BGM Group Niagen Bioscience Amphastar Pharmaceuticals Dyne Therapeutics AbCellera Biologics Phibro Animal Health Aura Biosciences (NASDAQ:AURA) and Structure Therapeutics (NASDAQ:GPCR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk. Which has more risk & volatility, AURA or GPCR? Aura Biosciences has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. Comparatively, Structure Therapeutics has a beta of -1.87, suggesting that its share price is 287% less volatile than the S&P 500. Which has better earnings & valuation, AURA or GPCR? Structure Therapeutics is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAura BiosciencesN/AN/A-$86.92M-$1.90-3.47Structure TherapeuticsN/AN/A-$122.53M-$0.87-23.70 Do institutionals and insiders have more ownership in AURA or GPCR? 96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 5.4% of Aura Biosciences shares are owned by company insiders. Comparatively, 9.4% of Structure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media refer more to AURA or GPCR? In the previous week, Aura Biosciences and Aura Biosciences both had 1 articles in the media. Structure Therapeutics' average media sentiment score of 1.02 beat Aura Biosciences' score of 0.00 indicating that Structure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Structure Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer AURA or GPCR? Aura Biosciences presently has a consensus target price of $22.00, suggesting a potential upside of 233.84%. Structure Therapeutics has a consensus target price of $76.17, suggesting a potential upside of 269.40%. Given Structure Therapeutics' higher probable upside, analysts plainly believe Structure Therapeutics is more favorable than Aura Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aura Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Structure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is AURA or GPCR more profitable? Structure Therapeutics' return on equity of -16.35% beat Aura Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Aura BiosciencesN/A -58.63% -49.74% Structure Therapeutics N/A -16.35%-15.71% SummaryStructure Therapeutics beats Aura Biosciences on 7 of the 13 factors compared between the two stocks. Get Aura Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AURA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AURA vs. The Competition Export to ExcelMetricAura BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$329.76M$2.89B$5.53B$9.04BDividend YieldN/A2.44%5.24%4.01%P/E Ratio-3.4721.7127.6620.25Price / SalesN/A281.11416.07118.18Price / CashN/A42.7336.8958.07Price / Book2.177.518.035.67Net Income-$86.92M-$55.14M$3.18B$249.21M7 Day Performance4.94%4.61%2.92%3.28%1 Month Performance8.03%4.72%3.72%5.55%1 Year Performance-5.99%5.92%35.14%21.08% Aura Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AURAAura Biosciences1.9042 of 5 stars$6.59+2.0%$22.00+233.8%-4.5%$329.76MN/A-3.4750GPCRStructure Therapeutics2.9266 of 5 stars$20.74-1.6%$76.17+267.2%-44.9%$1.21BN/A-23.84136Positive NewsCVACCureVac4.6413 of 5 stars$5.43+0.9%$6.83+25.8%+72.9%$1.21B$579.18M5.90880CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180AUPHAurinia Pharmaceuticals3.0945 of 5 stars$8.47-2.0%$11.50+35.8%+38.3%$1.17B$235.13M30.25300BGMBGM GroupN/A$10.59-11.5%N/AN/A$1.16B$25.10M0.00298NAGENiagen Bioscience1.332 of 5 stars$14.41+1.3%$19.50+35.3%N/A$1.12B$99.60M84.76120AMPHAmphastar Pharmaceuticals4.3673 of 5 stars$22.96-0.5%$32.33+40.8%-39.9%$1.09B$731.97M8.322,028News CoverageDYNDyne Therapeutics3.5041 of 5 stars$9.52-0.5%$41.13+332.0%-73.5%$1.09BN/A-2.65100ABCLAbCellera Biologics2.4871 of 5 stars$3.43-5.0%$8.33+143.0%+40.4%$1.08B$28.83M-6.12500High Trading VolumePAHCPhibro Animal Health3.6444 of 5 stars$25.54-0.5%$21.80-14.6%+63.3%$1.04B$1.02B32.741,940 Related Companies and Tools Related Companies Structure Therapeutics Competitors CureVac Competitors Calliditas Therapeutics AB (publ) Competitors Aurinia Pharmaceuticals Competitors BGM Group Competitors Niagen Bioscience Competitors Amphastar Pharmaceuticals Competitors Dyne Therapeutics Competitors AbCellera Biologics Competitors Phibro Animal Health Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AURA) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aura Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aura Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AURA Stock Alerts